It downregulates miR-155 in LPS-induced RAW 264.7 macrophages (173, 174).It reduced miR-21 and miR-155 in clinical studies.CUR inhibits p300 HAT in CVD experimental models (175–177).It inhibits HDAC I activity in cardiac cells (178).It inhibits HDAC I and HDAC III (179).It inhibits DNMTs in non-alcoholic fatty liver disease (180, 181). This evidence concerns the gene EP300 and metabolic dysfunction-associated steatotic liver disease.